Royal UNIBREW A/S
8.12.2025 10:37:35 CET | Globenewswire | Press release
Share buy-back program
Share buy-back program
Share buy-back program
On August 26, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 44/2025.
The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016.
The share buy-back program is expected to be realized in the period from August 27, 2025, to December 19, 2025. The total transaction value of the share buy-backs in the period will not exceed DKK 300m.
The following transactions on Nasdaq Copenhagen A/S have been made under the program:
| Number of Shares | Average purchase price DKK | Transaction value, DKK | |
| Accumulated, last announcement | 509,000 | 492.64 | 250,755,775 |
| December 1, 2025 | 4,000 | 566.35 | 2,265,400 |
| December 2, 2025 | 5,000 | 567.42 | 2,837,100 |
| December 3, 2025 | 5,000 | 563.45 | 2,817,250 |
| December 4, 2025 | 5,000 | 563.14 | 2,815,700 |
| December 5, 2025 | 6,000 | 558.37 | 3,350,220 |
| Total accumulated under the program | 534,000 | 495.96 | 264,841,445 |
With the transactions stated above Royal Unibrew owns a total of 1,137,042 shares, corresponding to 2.3% of the share capital. The total amount of shares in the company is 50,200,000, including treasury shares.
For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04
Encl.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Royal Philips24.8.2026 23:04:56 CEST | Press release
Philips prices EU green bond for EUR 650M
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
Lakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics24.8.2026 22:01:00 CEST | Press release
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Cosmos Health Inc.24.8.2026 21:40:00 CEST | Press release
Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories
Kitron ASA24.8.2026 17:07:52 CEST | Press release
Kitron revises full-year 2026 outlook upwards
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom